BRPI1007155A2 - métodos para tratar um distúrbio neurológico cortical, e para dispensar um agente terapêutico para o córtex em um primata - Google Patents

métodos para tratar um distúrbio neurológico cortical, e para dispensar um agente terapêutico para o córtex em um primata

Info

Publication number: BRPI1007155A2
Authority: BR; Brazil
Prior art keywords: primate; cortex; dispensing; treating; methods
Prior art date: 2009-01-29

Application number

BRPI1007155A

Other languages

English (en)

Inventor

P Kells Adrian

Bankiewicz Krystof

Original Assignee

Univ Of California San Francisco

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2009-01-29

Filing date

2010-01-29

Publication date

2017-05-30

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41796538&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI1007155(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2010-01-29 Application filed by Univ Of California San Francisco filed Critical Univ Of California San Francisco

2017-05-30 Publication of BRPI1007155A2 publication Critical patent/BRPI1007155A2/pt

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Genetics & Genomics (AREA)
Biomedical Technology (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Biotechnology (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Wood Science & Technology (AREA)
Zoology (AREA)
General Engineering & Computer Science (AREA)
Molecular Biology (AREA)
Psychiatry (AREA)
Plant Pathology (AREA)
Biochemistry (AREA)
Microbiology (AREA)
Epidemiology (AREA)
Biophysics (AREA)
Virology (AREA)
Physics & Mathematics (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Dermatology (AREA)
Pain & Pain Management (AREA)
Vascular Medicine (AREA)
Hospice & Palliative Care (AREA)
Urology & Nephrology (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

BRPI1007155A 2009-01-29 2010-01-29 métodos para tratar um distúrbio neurológico cortical, e para dispensar um agente terapêutico para o córtex em um primata BRPI1007155A2 (pt)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US14830209P	2009-01-29	2009-01-29
PCT/US2010/022659 WO2010088560A1 (en)	2009-01-29	2010-01-29	Methods for distributing high levels of therapeutic agent throughout the cortex to treat neurological disorders

Publications (1)

Publication Number	Publication Date
BRPI1007155A2 true BRPI1007155A2 (pt)	2017-05-30

Family

ID=41796538

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BRPI1007155A BRPI1007155A2 (pt)	2009-01-29	2010-01-29	métodos para tratar um distúrbio neurológico cortical, e para dispensar um agente terapêutico para o córtex em um primata

Country Status (9)

Country	Link
US (2)	US11305022B2 (pt)
EP (1)	EP2391388A1 (pt)
JP (2)	JP2012516357A (pt)
CN (1)	CN102369024A (pt)
AU (1)	AU2010208058A1 (pt)
BR (1)	BRPI1007155A2 (pt)
CA (1)	CA2751266A1 (pt)
CL (1)	CL2011001845A1 (pt)
WO (1)	WO2010088560A1 (pt)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP2391388A1 (en) *	2009-01-29	2011-12-07	University of California-San Francisco	Methods for distributing high levels of therapeutic agent throughout the cortex to treat neurological disorders
US20160237141A1 (en) *	2011-02-10	2016-08-18	Cedars-Sinai Medical Center	Methods of treating alzheimer's disease with apo a-1 milano
PT2879719T (pt) *	2012-08-01	2018-10-08	Ohio State Innovation Foundation	Administração intratecal do vírus adeno-associado 9 recombinante
GB201308917D0 (en) *	2013-05-17	2013-07-03	Renishaw Plc	Delivery
WO2015164778A1 (en)	2014-04-25	2015-10-29	The Trustees Of The University Of Pennysylvania	Ldlr variants and their use in compositions for reducing cholesterol levels
LT3137497T (lt)	2014-05-02	2021-07-26	Genzyme Corporation	Aav vektoriai, skirti tinklainės ir cns genų terapijai
CR20170407A (es)	2015-02-10	2017-11-14	Genzyme Corp	Mejora del suministro de partículas virales al cuerpo estriado y al córtex
CN115957350A (zh) *	2015-12-11	2023-04-14	宾夕法尼亚州大学信托人	用于治疗家族性高胆固醇血症的基因疗法
WO2018022511A1 (en)	2016-07-25	2018-02-01	The Trustees Of The University Of Pennsylvania	Compositions comprising a lecithin cholesterol acyltransferase variant and uses thereof
US11554147B2 (en)	2017-02-20	2023-01-17	The Trustees Of The University Of Pennsylvania	Gene therapy for treating familial hypercholesterolemia
CN116310602B (zh) *	2023-01-28	2025-08-15	华南理工大学	胎龄预测方法、装置、介质和设备

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4692147A (en)	1980-04-02	1987-09-08	Medtronic, Inc.	Drug administration device
US5139941A (en)	1985-10-31	1992-08-18	University Of Florida Research Foundation, Inc.	AAV transduction vectors
US5219740A (en)	1987-02-13	1993-06-15	Fred Hutchinson Cancer Research Center	Retroviral gene transfer into diploid fibroblasts for gene therapy
US5399346A (en)	1989-06-14	1995-03-21	The United States Of America As Represented By The Department Of Health And Human Services	Gene therapy
AU8200191A (en)	1990-07-09	1992-02-04	United States of America, as represented by the Secretary, U.S. Department of Commerce, The	High efficiency packaging of mutant adeno-associated virus using amber suppressions
US5173414A (en)	1990-10-30	1992-12-22	Applied Immune Sciences, Inc.	Production of recombinant adeno-associated virus vectors
DK0648271T3 (da)	1991-08-20	2003-07-21	Us Gov Health & Human Serv	Adenovirusmedieret overførsel af gener til mave-/tarmkanal
US5735815A (en)	1993-07-26	1998-04-07	Sentinel Medical, Inc.	Method of using fluid jet surgical cutting tool
WO1995005864A1 (en)	1993-08-27	1995-03-02	Government Of The United States Of America, Represented By The Secretary Of The Department Of Health And Human Services	Convection-enhanced drug delivery
US5576201A (en)	1994-01-14	1996-11-19	Alexion Pharmaceuticals, Inc.	Retroviral vector particles for transducing non-proliferating cells
US6351659B1 (en)	1995-09-28	2002-02-26	Brainlab Med. Computersysteme Gmbh	Neuro-navigation system
US6109815A (en)	1995-11-03	2000-08-29	Merlo; Werner O.	Joint mechanism
US6042579A (en)	1997-04-30	2000-03-28	Medtronic, Inc.	Techniques for treating neurodegenerative disorders by infusion of nerve growth factors into the brain
EP1621626B1 (en)	1998-05-27	2009-07-08	Genzyme Corporation	AAV Vectors for the manufacture of medicaments for convection enhanced delivery
EP1080202B1 (en)	1998-05-27	2006-01-25	Avigen, Inc.	Convection-enhanced delivery of aav vectors encoding aadc
WO2003004660A1 (en)	2001-07-03	2003-01-16	Institut National De La Sante Et De La Recherche Medicale (Inserm)	Methods of administering vectors to synaptically connected neurons
US20030050273A1 (en)	2001-08-29	2003-03-13	Keiya Ozawa	Compositions and methods for treating neurodegenerative diseases
GB2389791B (en)	2002-04-30	2006-12-13	Steven Gill	Implantable drug delivery pump
EP3067070A1 (en)	2002-09-24	2016-09-14	The Government of the United States of America as represented by the Secretary of the Department of Health and Human Services	Method for convection enhanced delivery of therapeutic agents
US20060171926A1 (en)	2004-04-30	2006-08-03	Passini Marco A	Gene therapy for neurometabolic disorders
CA2581714C (en)	2004-10-05	2017-09-12	Avigen, Inc.	Stepped cannula
US20060129126A1 (en) *	2004-11-19	2006-06-15	Kaplitt Michael G	Infusion device and method for infusing material into the brain of a patient
US9089667B2 (en)	2005-08-23	2015-07-28	The Regents Of The University Of California	Reflux resistant cannula and system for chronic delivery of therapeutic agents using convection-enhanced delivery
WO2007127839A2 (en)	2006-04-26	2007-11-08	The Regents Of The University Of California	Compositions and methods for convection enhanced delivery of high molecular weight neurotherapeutics
EP2212348B1 (en) *	2007-11-02	2015-07-15	Cornell University	Materials and methods for gene mediated therapy of psychiatric disorders
EP2391388A1 (en) *	2009-01-29	2011-12-07	University of California-San Francisco	Methods for distributing high levels of therapeutic agent throughout the cortex to treat neurological disorders

2010
- 2010-01-29 EP EP10703579A patent/EP2391388A1/en not_active Withdrawn
- 2010-01-29 AU AU2010208058A patent/AU2010208058A1/en not_active Abandoned
- 2010-01-29 BR BRPI1007155A patent/BRPI1007155A2/pt not_active IP Right Cessation
- 2010-01-29 CA CA2751266A patent/CA2751266A1/en not_active Abandoned
- 2010-01-29 CN CN2010800109540A patent/CN102369024A/zh active Pending
- 2010-01-29 WO PCT/US2010/022659 patent/WO2010088560A1/en not_active Ceased
- 2010-01-29 JP JP2011548357A patent/JP2012516357A/ja active Pending
- 2010-01-29 US US13/146,640 patent/US11305022B2/en active Active
2011
- 2011-07-29 CL CL2011001845A patent/CL2011001845A1/es unknown
2015
- 2015-02-02 JP JP2015018554A patent/JP2015083614A/ja not_active Withdrawn
2022
- 2022-03-17 US US17/697,841 patent/US12370270B2/en active Active

Also Published As

Publication number	Publication date
US11305022B2 (en)	2022-04-19
CN102369024A (zh)	2012-03-07
US20220347319A1 (en)	2022-11-03
CA2751266A1 (en)	2010-08-05
EP2391388A1 (en)	2011-12-07
WO2010088560A1 (en)	2010-08-05
JP2015083614A (ja)	2015-04-30
AU2010208058A1 (en)	2011-08-18
CL2011001845A1 (es)	2012-07-13
US20120027726A1 (en)	2012-02-02
JP2012516357A (ja)	2012-07-19
US12370270B2 (en)	2025-07-29

Publication	Publication Date	Title
BRPI1007155A2 (pt)	2017-05-30	métodos para tratar um distúrbio neurológico cortical, e para dispensar um agente terapêutico para o córtex em um primata
IL237743A0 (en)	2015-05-31	A combination of rasagiline and pridofidine for the treatment of neurodegenerative diseases, and specifically for the treatment of Huntington's disease
GB2463797B (en)	2010-08-25	Skin treating device
BRPI0817741A2 (pt)	2015-03-31	Composição para tratamento de tecidos, e, processo de lavagem para deposição de partículas pró-bióticas em tecidos
BR112015009312A2 (pt)	2017-07-04	dispositivo para tratar, em particular modelar, o cabelo e processo para tratar o cabelo com o auxílio de um dispositivo de tratamento.
EP2222359A4 (en)	2014-03-12	DEVICES AND METHOD FOR TREATMENT OF BREATHING IN SLEEP
EP2240239A4 (en)	2013-11-27	METHOD AND DEVICE FOR TREATING BRAIN SPECIFIC CHRONIC PAIN
BR112015015977A2 (pt)	2018-05-15	aparelho com movimento elíptico para limpeza de pele, estimulação e distribuição de tratamentos
BR112015003397A2 (pt)	2019-09-24	composto, composição farmacêutica, uso do composto e método para tratar uma doença ou condição mediada por rorgammat em um paciente.
IL212707A0 (en)	2011-07-31	Compounds, pharmaceutical composition and methods for use in treating metabolic disorders
IL202424A (en)	2017-01-31	Telomerase activator compounds for use in the treatment of disorders and related conditions
IL229466A0 (en)	2014-01-30	2-sglt inhibitors for the treatment of metabolic disorders in patients treated with neuroleptic agents
PL2359781T3 (pl)	2014-06-30	Urządzenie do wykonywania zabiegów upiększających, fizjoterapeutycznych i hydroterapuetycznych
PL2083837T3 (pl)	2015-06-30	Terapeutyczne zastosowanie co najmniej jednej neurotoksyny botulinowej do leczenia bólu wywołanego co najmniej jednym środkiem przeciwnowotworowym
EP2219448A4 (en)	2011-10-12	THERAPEUTIC COMPOUNDS AND THEIR USE IN THE TREATMENT OF DISEASES AND SUFFERINGS
IL211534A0 (en)	2011-05-31	Sulfur-linked compounds for treating ophthalmic diseases and disorders
ZA201000173B (en)	2010-09-29	Method for treating an at least partially metallised textile, treated textile and the use thereof
BRPI0918103A2 (pt)	2016-07-05	"método para o tratamento da dor em um indivíduo"
EP2274411A4 (en)	2016-01-20	XANTHOHUMOL COMPOSITIONS AND METHODS FOR TREATING SKIN DISEASES OR CONDITIONS
ZA201300954B (en)	2014-04-30	Methods for treating and/or reversing neurodegenerative deseases and/or disorders
EP2413837A4 (en)	2013-10-23	METHODS FOR TREATING MYOFASCIAL, MUSCLE AND / OR BACK PAIN
BRPI1003991A2 (pt)	2015-09-15	métodos para dosagem de uma aminopiridina, para tratamento de um distúrbio neurocognitivo ou neuropsiquiátrico, e, para preparação de um medicamento
BRPI0924398A2 (pt)	2019-09-24	perexilina, metodo de tratamento de hfnef e programa de tratamento para tratar hfnef
BRPI0907723A2 (pt)	2015-07-14	Métodos e composições para o tratamento de doença respiratória
ZA200810199B (en)	2010-01-27	Rinse-off therapeutic agents for treating skin

Legal Events

Date	Code	Title	Description
2017-06-06	B08F	Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
2017-09-19	B08K	Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]